key: cord-0974004-lr60qhzc
authors: Armstrong, Lee A.; Lange, Sven M.; de Cesare, Virginia; Matthews, Stephen P.; Nirujogi, Raja Sekar; Cole, Isobel; Hope, Anthony; Cunningham, Fraser; Toth, Rachel; Mukherjee, Rukmini; Bojkova, Denisa; Gruber, Franz; Gray, David; Wyatt, Paul G.; Cinatl, Jindrich; Dikic, Ivan; Davies, Paul; Kulathu, Yogesh
title: Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies
date: 2020-12-09
journal: bioRxiv
DOI: 10.1101/2020.12.09.417741
sha: 368628a09cebdcffa07a41b47b9209355aca8caa
doc_id: 974004
cord_uid: lr60qhzc

Of the 16 non-structural proteins (Nsps) encoded by SARS CoV-2, Nsp3 is the largest and plays important roles in the viral life cycle. Being a large, multidomain, transmembrane protein, Nsp3 has been the most challenging Nsp to characterize. Encoded within Nsp3 is the papain-like protease PLpro domain that cleaves not only the viral protein but also polyubiquitin and the ubiquitin-like modifier ISG15 from host cells. We here compare the interactors of PLpro and Nsp3 and find a largely overlapping interactome. Intriguingly, we find that near full length Nsp3 is a more active protease compared to the minimal catalytic domain of PLpro. Using a MALDI-TOF based assay, we screen 1971 approved clinical compounds and identify five compounds that inhibit PLpro with IC50s in the low micromolar range but showed cross reactivity with other human deubiquitinases and had no significant antiviral activity in cellular SARS-CoV-2 infection assays. We therefore looked for alternative methods to block PLpro activity and engineered competitive nanobodies that bind to PLpro at the substrate binding site with nanomolar affinity thus inhibiting the enzyme. Our work highlights the importance of studying Nsp3 and provides tools and valuable insights to investigate Nsp3 biology during the viral infection cycle.

COVID-19 has taken a significant toll on human life and has impacted society in unprecedented ways. Therefore, understanding the mechanisms by which SARS-CoV-2 interacts with human cells and the functions of the different viral proteins in establishing infection is of paramount importance. The genome of SARS-CoV-2 encodes 16 non-structural proteins (Nsps) which play different roles in the viral life cycle (Wu et al, 2020) . Nsp3, the largest of the Nsps, is a 217 kDa multidomain membrane protein that is a key component of the viral replication and transcription complex assembled on host cell membranes where replication and transcription of the viral genome occurs (Angelini et al, 2013; Wolff et al, 2020a Wolff et al, , 2020b . Another essential role of Nsp3 is its function as a protease. Encoded within Nsp3 is the papain-like protease (PLpro CoV-2 ) that cleaves between Nsp1-Nsp2, Nsp2-Nsp3 and Nsp3-Nsp4 to release Nsp1, Nsp2 and Nsp3 from the viral polypeptide. While several coronaviruses express two PLpro enzymes, SARS-CoV-2 only expresses one PLpro enzyme (Barretto et al, 2005) .

PLpro CoV-2 shows many similarities to the PLpro encoded by SARS, PLpro SARS . The structure of PLpro is similar to that of human ubiquitin specific protease (USP) deubiquitinating enzymes (DUBs), which resembles an extended or open hand with thumb, palm and fingers subdomains that mediate contacts with substrate to form the S1 site (Shin et al, 2020; Klemm et al, 2020; Ratia et al, 2014; Chou et al, 2014) . In addition to processing viral polypeptides, PLpro possesses deubiquitylating and deISGylating activities as it can also efficiently cleave ubiquitin and ISG15 modifications (Bailey-Elkin et al, 2017) . Ubiquitylation and ISGylation, the covalent attachment of ubiquitin and the ubiquitin-like modifier (Ubl) ISG15 respectively to proteins, are important posttranslational modifications (PTMs) in host innate immune antiviral and inflammatory signalling pathways (Swatek & Komander, 2016) . ISG15 is an interferon-stimulated gene whose expression is induced following viral infection and is important to host antiviral responses (Perng & Lenschow, 2018) . PLpro SARS has a unique mode of action as it recognizes ubiquitin at an additional S2 ubiquitin-binding site in order to bind and cleave K48-linked ubiquitin chains from substrates (Békés et al, 2015 (Békés et al, , 2016 . ISG15 contains two connected Ubl domains which together resemble diubiquitin that can bind to the S1 and S2 sites. These additional protease activities of PLpro antagonize host ubiquitylation and ISGylation to effectively subvert antiviral signalling and the host immune response. These multifaceted roles of PLpro render it essential for viral replication, thereby making it an attractive therapeutic target for Given the large size of Nsp3, PLpro and the other domains in Nsp3 have each been individually characterized in detail. However, most studies have examined only the minimal proteolytic PLpro domain and there is little known about the influence of the other domains in Nsp3 on protease activity and function. In the present study, we perform detailed biochemical characterization of minimal PLpro CoV-2 and compare it with the protease activity of Nsp3 CoV-2 . We make the surprising observation that extended Nsp3 is a more active protease cleaving both ISG15 and K48-linked chains with greater efficiency. Intriguingly, while Nsp3 can very efficiently cleave the viral polypeptide Nsp1-Nsp2, the minimal PLpro is unable to cleave this fusion. To find inhibitors of PLpro, we employed a high-throughput MALDI TOF-based assay to screen 1971 FDA approved compounds and identify inhibitors of the protease with IC50 values in the 1-10 µM range. Despite displaying good inhibition in vitro, none of the inhibitors show any efficacy in blocking viral replication in a SARS-CoV-2 viral infection model. We therefore engineered nanobodies that bind to and inhibit PLpro in the nanomolar range. These nanobodies will be valuable tools to identify cellular substrates of Nsp3 and to investigate Nsp3 biology.

PLpro is a multifunctional enzyme with three distinct protease activities that catalyse the cleavage of (i) K48-linked polyubiquitin, (ii) ISG15 and (iii) viral polypeptides. To understand how PLpro can cleave these structurally distinct substrates and to characterize these three activities further, we first generated appropriate substrates.

As previously observed for PLpro SARS , PLpro CoV-2 is also selective at cleaving K48linked chains (Fig 1B, S1A) , and shows a similar mode of cleavage by cleaving triubiquitin into diubiquitin and monoubiquitin as final products (Békés et al, 2015) .

Monitoring the cleavage of proISG15, which carries an 8-residue peptide at the Cterminus of ISG15, shows that PLpro is also very active towards ISG15 (Fig 1B) .

Processing of the viral polypeptide involves cleavage between Nsp1-Nsp2, Nsp2-Nsp3 and Nsp3-Nsp4 (Fig 1A) . To monitor the cleavage of the viral polypeptide, we expressed and purified full length Nsp1 fused to the first 19 amino acids of Nsp2 (Nsp1-2Δ). When used as a substrate in cleavage assays, we were surprised to find that PLpro is unable to cleave Nsp1-2Δ (Fig. 1B) . To confirm this observation, we incubated increasing concentrations of PLpro with Nsp1-2Δ, which was still resistant to cleavage (Fig. S1B) .

We wondered if recognition elements outside the minimal PLpro domain might be responsible for detection and cleavage of Nsp1-2Δ. Nsp3 is a multidomain protein containing a transmembrane segment that mediates its localization to membrane vesicles (Fig 1A) (Imbert et al, 2008; Lei et al, 2018) . In addition to the protease domain, Nsp3 contains an N-terminal Ubl (ubiquitin-like domain) followed by an ADRP (ADP-ribose phosphatase, SUD (SARS-unique domain) domain, another Ubl domain that is part of PLpro. C-terminal of the protease is a NAB (nucleic acid binding) domain followed by a TM (transmembrane segment) and a ZnF (zinc finger) domain at the very C-terminus (Lei et al, 2018; Tan et al, 2009 ). Despite being a large multidomain protein, we obtained milligram amounts of pure and stable recombinant Nsp3 truncations when we either removed or replaced the transmembrane segment and the acidic stretch at the N-terminus with a linker (Fig 1C) . As all the Nsp3 variants were equally active (Fig S1C) , Nsp3 spanning residues 179-1329 (henceforth referred to as Nsp3) was chosen for further characterization. We first compared cleavage efficiency of the three substrates using 50 µM Nsp3, the same concentration as that of PLpro used in Fig 1B, which revealed that extended versions of Nsp3 unlike PLpro actively cleaved all three substrates including Nsp1-2Δ (Fig 1D) . The C-terminus of all PLpro substrates contains a -GG motif, with PLpro cleaving after the last Gly ( Fig   S1D) . Indeed, mutating the C-terminal G180 of Nsp1 renders it resistant to cleavage by Nsp3 as does mutation of the catalytic C856 of Nsp3 to Ala (Fig 1E, S1E) , confirming that the extended Nsp3 maintains substrate specificity and does not contain additional protease catalytic sites. We then made propargylated Nsp1 (Nsp1 Prg ), a reactive probe which would covalently modify the catalytic Cys of PLpro and Nsp3 (Ekkebus et al, 2013) . Indeed, while Nsp3 was efficiently modified by Nsp1 Prg , barely any conversion was observed for PLpro (Fig S1F) . The Nsp1-2 substrate tested so far only contains 19 amino acids from Nsp2. To test if the presence of intact Nsp2 made a difference, we expressed and purified Nsp1-Nsp2 full length fusions. When used as substrate, we again find that PLpro is still unable to cleave this substrate whereas Nsp3 is efficient at cleaving it (Fig 1F) .

We next compared the activities of PLpro and Nsp3 for each of the substrates in qualitative gel-based assays. With polyubiquitin, nearly all triubiquitin is cleaved by Nsp3 (50 nM) after 15 minutes whereas a significant portion is still to be cleaved by PLpro (Fig 1G, top) . Similarly, Nsp3 (20 nM) cleaves most of the pro-ISG15 by 15 minutes while only ~50% is cleaved by PLpro (Fig 1G, lower) . With the Nsp1-2Δ substrate, Nsp3 (1 μM) is able to cleave, whilst PLpro is not (Fig. 1H ) These qualitative assays suggest that Nsp3 is a more active enzyme. To confirm these observations, we used a MALDI TOF based DUB assay (Ritorto et al, 2014) , which shows that PLpro efficiently cleaves K48 trimers with a Km of 29.39 µM, a Vmax of 0.66 µM*min -1 and a kcat of 22 min -1 (Fig S1G) . In contrast, Nsp3 cleaves K48-linked triubiquitin with a Km of 17.79 µM, a Vmax of 0.62 µM*min -1 and a kcat of 20.6 min -1 . The comparatively lower Km of Nsp3 potentially explains the higher cleavage activity observed. Even though Nsp3 is more active than PLpro, it still retains its specificity for cleaving K48-linked polyubiquitin and does not cleave any of the other linkages tested (Fig 1I) .

Despite several attempts, we were unable to crystallize longer variants of Nsp3 on its own or in complex with a substrate. Intriguingly, Nsp3 elutes at an apparent molecular weight of ~520kDa on a size-exclusion chromatography column raising the possibility that it could be tetramer (Fig 1J) . However, mass photometry analysis reveals Nsp3 to be a monomer (Fig 1K) , suggesting that the behaviour on gel filtration could be attributed to an extended conformation or coiled-coil content in Nsp3. Obtaining a structure of Nsp3 in complex with its substrate might reveal why it is more active compared to PLpro and why it can cleave Nsp1-Nsp2.

Since we observe differences in protease activity between Nsp3 and PLpro, we next Quantitative mass spectrometry analysis revealed that Nsp3 DTM and PLpro had a largely overlapping interactome (Figure 2) . Interestingly, many of the interactors enriched for both PLpro and NSP3 DTM are interferon stimulated and proteins involved in antiviral signalling. With its preference for cleaving ISG15, we observed ISG15 as a significant interactor that was also identified in the PLpro CoV-2 interactome (Shin et al, 2020). Other prominent overlapping interactors include the IFITs (Interferoninduced protein with tetratricopeptide repeats), IFIT1 and IFIT2, antiviral proteins that function as sensors of viral single-stranded RNAs to inhibit expression of viral messenger RNAs (Diamond & Farzan, 2013) . Nsp3 DTM also interacts with the antiviral proteins SAMHD1, which binds to nucleotides and depletes cellular dNTPs, and 1'-5'-oligoadenylate synthase 3 (OAS3), another interferon-induced gene that inhibits viral replication by degrading viral RNA (Li et al, 2016) . In addition, both PLpro and Nsp3 DTM interact with the multifunctional ATP-dependent RNA helicase DDX3X, which promotes IRF3 activation leading to the production of the type I interferons, IFNa and IFN-b (Soulat et al, 2008) .

Our data also identifies interactors linked to translation (EIF5A2, EIF2S1, ICE1, EIF2S3L) and the actin cytoskeleton (Cofilin-1, tubulins, KIF9, MYL4, PDLIM5), which was also observed in a recent study that used proximity labelling (Laurent et al, 2020) .

While most interactors are largely overlapping between Nsp3 DTM and PLpro, we identify the RNA binding protein Fragile X mental retardation syndrome-related protein 1 (FXR1) to be enriched only in Nsp3 DTM pull downs. Interestingly, Nsp3 from Sindbis virus interacts with FXR1 to bind viral RNAs for the assembly of viral replication complexes (Kim et al, 2016) .

Despite having several additional domains, no additional unique interactors were identified for Nsp3 DTM. We attribute the lack of additional interactions to Nsp3 DTM to the following possibilities: (i) the Nsp3 used in our experiments lacks the transmembrane segment and hence does not localize to the right subcellular compartment where the relevant cellular interactors of Nsp3 may be present; (ii) the majority of the interactions with Nsp3, i.e., the Ubl1 domain, the SUD domain and macrodomain are with RNA or ADP-ribose, and (iii) Nsp3 has been suggested to function as a scaffold mediating binding to other Nsps to form replicative organelles explaining the lack of interactions with human proteins. Indeed, several interactions of Nsp3 with other viral Nsps have been identified by Y2H, but the functional implications of these interactions to the viral life cycle are unclear (Pan et al, 2008; Imbert et al, 2008; von Brunn et al, 2007) .

We employed the previously developed MALDI-TOF DUB assay (Ritorto et al, 2014) to evaluate the ability of 1971 FDA approved drugs to inhibit PLpro from SARS-CoV-2. Importantly the bioactivity and safety of these compounds has been tested in clinical trials allowing rapid repurposing of any hit compounds into therapies for the treatment of COVID-19. Compared to other fluorescent-based approaches, the MALDI-TOFbased assay has the advantage of using K48 ubiquitin trimer, a physiological PLpro substrate, for high-throughput screening (HTS) (De Cesare et al, 2020) . Further, the final products generated upon cleavage of triubiquitin are diubiquitin and monoubiquitin, which makes it compatible for analysis using the MALDI DUB assay.

The reaction is terminated by the addition of 2% TFA and 15 N ubiquitin. To circumvent the spot-to-spot variability typical for MALDI-TOF based detection, the mono-ubiquitin signal is normalized to the 15 N internal standard signal ( Figure 3A) . The FDAapproved drug library was screened in duplicate at a concentration of 10 μM. The Z' value is commonly employed to determine the robustness of HTS, with Z' values greater than 0.5 indicating a robust assay (Zhang et al, 1999) . The MALDI-TOF DUB assay resulted in an average Z' value of 0.77 ± 0.12 ( Figure 3B ). Compounds returning percentage inhibition values >50% were identified as hits and 30 compounds met this criterion (1.5 % hit rate) ( Figure 3B ). The hit compounds were cherry picked and retested in a 10-point dose-response to determine IC50 values against both PLpro and Nsp3. The MALDI-TOF-based results were further validated by orthogonal, gelbased assays employing K48-linked triUb and pro-ISG15 as substrate ( Figure 3D ;

Based on these analyses, five compounds were confirmed for their ability to inhibit PLpro and Nsp3 in vitro (confirmation rate = 16.6%): Thioguanine, Nordihydroguaiaretic acid, Disulfiram, Auranofin and Tideglusib ( Figure 3C ).

Thioguanine inhibits PLpro and Nsp3 with IC50 of 4.54 and 8.67 µM respectively, in the MALDI-TOF-based assay. Intriguingly, despite this reasonable IC50, we could not observe inhibition of PLpro by Thioguanine in the orthogonal gel-based assay Interestingly, thioguanine was previously found to inhibit PLpro SARS (Báez-Santos et al, 2015) and SARS-CoV-2 replication (Swaim et al, 2020) .

In our assays, we identify nordihydroguaiaretic acid (NDA) to be a potent inhibitor of PLpro and Nsp3, with IC50 of 1.06 and 1.62 µM in the MALDI-TOF based assay. NDA is a compound extracted from plants, used in traditional medicine for the treatment of various diseases, and found to inhibit numerous cellular targets (Manda et al, 2020).

Its ability to inhibit a range of cysteine-based enzymes is linked to the redox properties of its two catechol rings, resulting in the formation of cysteine adducts (Manda et al, 2020) . Despite its beneficial effects, the main drawback to the use of this compound is its potential renal and liver toxicity over prolonged use.

Disulfiram is a thiocarbamate drug (commercially available as Antabuse®) that has received FDA approval for the treatment of alcoholism and has been in use for more than 60 years (Johansson, 1992) . Disulfiram has been previously identified by in silico screening and fluorescence resonance energy transfer assay to inhibit the main SARS-CoV-2 Cys-protease, Mpro (Lobo-Galo et al, 2020; Jin et al, 2020) . Disulfiram also inhibits PLpro CoV2 and Nsp3 with similar potencies, 0.69 and 0.66 µM in the MALDI-TOF-based assay, and between 1 and 2.5 µM when assessed by gel-based orthogonal assay (Figure 3D-E) . Tideglusib, a Glycogen Synthase Kinase 3 (GSK3) inhibitor, has also been found to inhibit the main SARS-CoV-2 Cys-protease (Jin et al, 2020). We found that Tideglusib strongly inhibits both PLpro and Nsp3 with IC50 of 0.21 and 1.48 µM, respectively in the MALDI-TOF based assay. Similar potency of Tidegusib was also validated in the gel-based assay ( Figure 3D -E). Auranofin is a gold-containing compound employed for the treatment of rheumatoid arthritis (Roder & Thomson, 2015) , known to suppress inflammation and stimulating cell-mediated immunity. Of note, Auranofin has been recently shown to inhibit replication of SARS-CoV-2 in human cells (Rothan et al, 2020) . Interestingly, we found that Auranofin strongly inhibits PLpro and Nsp3 with potency in the 1 µM range in the MALDI-TOF based assay with a similar inhibition pattern observed in the gel-based assay ( Figure   3D -E). We then tested GRL-0617, a non-covalent inhibitor identified to inhibit PLpro SARS , following the outbreak of SARS in 2002-2003, with an IC50 of 0.6 µM (Ratia et al, 2008) . We found that GRL-0617 also inhibits PLpro with an IC50 of 2.21 µM and Nsp3 with an IC50 of 3.39 µM ( Figure 3F ). The high sequence similarity between PLpro from SARS-CoV and SARS-CoV-2 and the conserved active site explain why GRL-0617 inhibits both proteases. Figure 3G ). Interestingly, GRL-0617 was also able to inhibit cleavage of the viral polypeptide ( Figure S3D ) The presence of highly reactive chemical groups able to covalently modify reactive cysteines might explain the poor specificity of these small molecules. Despite the broad range of activity of these compounds, their relative safety has been extensively evaluated in FDA pre-clinical and clinical trials.

We next tested the efficacy of these compounds to inhibit PLpro in cell-based assays measuring activation of interferon expression using an IFN-b luciferase reporter or the ability to inhibit replication of SARS-CoV-2 in CaCo cells (Shin et al, 2020) . To our disappointment, none of the compounds other than GRL-0617 showed any effects of inhibiting PLpro in cells (data not shown). These results are in contrast to what was shown for some of these inhibitors. For instance, the use of Auranofin and thioguanine has been shown to limit SARS-CoV-2 replication (Swaim et al, 2020; Rothan et al, 2020) but the underlying mechanism of action is not entirely understood. Our data demonstrate that Auranofin and thioguanine inhibit the deubiquitinating activity of the PLpro protease in vitro. The low potency of the identified hits at limiting viral replication suggests that repurposing may not be an effective strategy to identify inhibitors suitable for clinical development and a systematic approach is required to develop specific and effective inhibitors of PLpro/Nsp3. Our results, showing that extended versions of Nsp3 can cleave viral polypeptides, which the minimal PLpro is not as efficient at suggest that using Nsp3 to screen for inhibitors could lead to the identification of allosteric inhibitors that may inhibit all three activities of Nsp3. Despite not being very potent on their own, combining drugs targeting essential SARS-CoV-2 proteases (PLpro and/or main protease) with other essential viral enzymes such as RNA-dependent polymerase may represent a therapeutic strategy.

Since all the identified inhibitors identified show off-target effects and inhibit other human DUBs, we wanted to devise other ways to selectively inhibit PLpro as a strategy to investigate the roles of Nsp3 in the viral life cycle, in interfering with host immune signalling and to examine if inhibition of PLpro can effectively block viral replication.

Previously, ubiquitin variants (Ubv) have been developed to selectively inhibit DUBs by binding to the S1 pocket (Zhang et al, 2017; Gorelik & Sidhu, 2017) . Hence, we aimed to engineer a nanobody that binds to the S1 site with high affinity to inhibit PLpro. Further, the S1 site is important for both deubiquitinating and deISGylating activities of PLpro (Békés et al, 2016) . We therefore used a recently developed yeast surface nanobody display library that was developed recently to screen and identify nanobodies (McMahon et al, 2018) . To steer nanobody selection towards the S1 site, we had to discard nanobodies that recognized other regions of PLpro. Hence, we introduced a negative selection step using PLpro CoV-2 carrying mutations in the S1 site.

As these mutations were designed based on the available structure of PLpro SARS in complex with ubiquitin (PDB 4MM3, (Ratia et al, 2014) ) (Fig S4A) , we first tested if these mutations also affected PLpro CoV-2 . Indeed, compared to WT, the mutant PLpro CoV-2 was unreactive to propargylated Ub and was unable to cleave K48-linked triUb (Fig S4B-C) . Following multiple rounds of negative and positive selection using magnetic-activated cell sorting (MACS), as outlined in Fig 4A , single yeast clones were tested for their binding to PLpro (Fig 4B) . Excitingly, we identified several nanobodies that bound to WT PLpro CoV-2 but not the S1 site mutant, suggesting that these nanobodies specifically bind to the S1 site 19) . Sequencing these nanobodies revealed differences in the CDR1, CDR2 and CDR3 loops of the different nanobodies.

To further characterize these nanobodies, they were recombinantly expressed and purified from bacteria. Of the three individual nanobody sequences we identified, soluble expression was obtained for only two nanobodies (NbSL17 and NbSL18). We first performed analytical gel filtration, which identified NbSL18 to form a complex with PLpro CoV-2 (Fig 4C) . Using isothermal titration calorimetry (ITC), we find the binding affinity of NbSL18 for PLpro CoV-2 to be ~500nM (Fig 4D) . Intriguingly, we do not observe any detectable binding of PLpro for K48-linked diUb or ISG15 by ITC (Fig   4E,F) . Since NbSL18 binds to PLpro with higher affinity compared to K48-linked diUb, we next evaluated the ability of NbSL18 to inhibit PLpro. With increasing concentration of NbSL18, the cleavage of K48-linked triUb by PLpro is inhibited with ~50% inhibition at 500nM NbSL18, which is consistent with the binding affinity of NbSL18 for PLpro ( Fig 4G) . In contrast, higher concentrations of NbSL18 are required to inhibit the cleavage of ISG15. Recent crystal structures of ISG15 in complex with PLpro show that the C-terminal UBL of ISG15 uses a slightly different mode of interaction compared to ubiquitin (Shin et al, 2020; Klemm et al, 2020) , thus explaining the differences in the inhibition of deubiquitylating and deISGylating activities by NbSL18.

Understanding how the viral polypeptide is recognised by Nsp3, and building on this to inhibit release of mature Nsp1/2/3, could represent a legitimate strategy to suppress viral replication. Nsp1, for instance, plays a key role in the infection process by binding to host 40S ribosomal subunits and blocking the mRNA channel with its C-terminal domain, thereby suppressing translation of host proteins and sequestering ribosomes for translation of viral proteins. Preventing Nsp1 maturation from the viral polypeptide could therefore be vital in hindering viral replication (Schubert et al, 2020; Thoms et al, 2020) . We therefore tested if NbSL18 could also inhibit cleavage of Nsp1-Nsp2 FL fusions. Excitingly, our data reveals that NbSL18 can indeed inhibit Nsp1-2 FL cleavage by Nsp3 suggesting that the viral peptide also occupies the same S1 site as ubiquitin (Fig 4H) .

Determining a crystal structure of NbSL18 in complex with Nsp3 or PLpro would shed light into the mode of interaction and allow us to engineer mutations to not only increase the binding affinity but also selectively inhibit deubiquitylating, deISGylating or viral polypeptide processing activities. However, despite several attempts we were unable to obtain well-diffracting crystals. Nevertheless, the nanobodies developed here would be valuable tools to dissect the relative contributions of the three different peptidase activities of Nsp3 to viral replication and infection. In summary, our work reveals differences in protease activities between the minimal PLpro domain of Nsp3 and longer versions of Nsp3 and highlights the need to study the mechanism of Nsp3.

Further, current efforts to develop inhibitors are focussed solely on PLpro and our findings suggest that it would be important to evaluate not only their efficacy at inhibiting full length Nsp3, but also the ability of the protease to cleave viral polypeptides.

This work is dedicated to the memory of Anthony Hope who was passionate about this project and identifying potent inhibitors of PLpro to treat COVID-19. 

The authors declare no competing interests. Figures S1-S4 and Tables S1-2.

Human ISG15 cDNA was amplified by RT-PCR from universal human reference RNA (Agilent 740000-41), adding BamHI and NotI restriction sites at the 5' and 3' ends respectively. The digested PCR product was cloned into pGEX6P1 cut with the same enzymes to make pGEX6P1 ISG15 (DU8371).

Ubiquitin cDNA was amplified from existing clone DU8724 (pET15b 6His 3C Ubiquitin), adding restriction sites NdeI and BamHI at the 5' and 3' ends, respectively.

The digested PCR product was cloned into pET24a cut with the same enzymes to make pET24a Ubiquitin (DU20027).

The cDNAs coding for SARS CoV-2 (MN908947.3) Nsp3 residues 743-1072 (PL-pro) and SARS CoV-2 Nsp3 residues 743-1072 (PL-pro) E912R E948R M953E Y1013K were synthesised by NBS Biologicals (www.nbsbio.co.uk) with 5' BamHI and 3' NotI sites. Sequences were codon optimised for bacterial expression. These were subcloned into receptor vector pETDuet 6His TEV GST 3C AVi (DU68478) digested with BamHI and NotI to make pETDuet 6His TEV GST 3C AVi SARS CoV-2 Nsp3 PLpro (DU67765) and pETDuet 6His TEV GST 3C AVi SARS CoV-2 Nsp3 PL-pro E912R E948R M953E Y1013K (DU67766).

pETDUET 6HIS TEV GST 3C SARS-CoV-2 Nsp3 743-1072 (PL-pro) (DU67811) was made by removing the avi tag sequence from DU67765 by PCR mutagenesis.

The cDNA coding for SARS CoV-2 Nsp1 1-180 Nsp2 1-19 8His was synthesised by GeneArt (Thermo Fisher Scientific) adding NcoI and NotI sites at the 5' and 3' ends, respectively. This sequence was subcloned into pET28a to make pET28a SARS-CoV-2 Nsp1 1-180 Nsp2 1-19 8His (DU67799). See Table S1 for summary of constructs used in this study. All constructs described here can be obtained from https://mrcppu-covid.bio/

All recombinant proteins were expressed in E. coli BL21-CodonPlus (DE3) cells.

Bacterial cultures were grown in 2x TY media supplemented with 100 µg/ml ampicillin to an OD600 of 0.6-0.8 at 37˚C in shaking incubators. Protein expression was induced by the addition of 300 µM IPTG followed by overnight incubation at 18˚C. Cells were harvested at 4200 rpm for 30 minutes and pellets were suspended in lysis buffer (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 10% glycerol, 0.075% v/v BME, 1 mM benzamidine, 1 mM AEBSF and a complete protease inhibitor cocktail tablet (Roche).

Resuspended cells were then lysed by sonication and clarified by centrifugation at 35,000g for 45 min at 4˚C.

Clarified lysate was incubated with His60 Ni Superflow Resin (TaKaRa) for 1 hr at 4˚C.

Resin was washed with buffer (300 mM NaCl, 50 mM Tris pH 7.5) supplemented with increasing concentrations of imidazole. Protein was eluted with 300 mM Imidazole.

The eluent was then incubated with GSH Sepharose (BRAND) for 1 hour before being washed by high salt buffer (500 mM NaCl, 50 mM Tris pH 7.5, 5 10 mM DTT) and then low salt buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1 mM DTT). Resin was incubated with low salt buffer supplemented with PreScission protease o/n at 4˚C to cleave the GST tag. Protein was eluted and concentrated (Amicon Centrifugal Filter Units, Merck) followed by size exclusion chromatography (Superdex 75 16/60, Cytiva) in a suitable buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT).

The clarified lysate was then filtered through a 0.45-micron syringe filter and purified by affinity chromatography (StrepTrap, Cytiva). The column was washed thoroughly with buffer S (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM DTT) and protein was eluted with buffer S supplemented with 10 mM desthiobiotin. The protein was then further purified by anion exchange chromatography (Resource Q, Cytiva) and eluted in a gradient with buffer Q (50 mM Tris-HCl pH 8.5, 1 M NaCl, 1 mM DTT), followed by size exclusion chromatography (Superdex 200 16/60, Cytiva) in a suitable buffer (20 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM DTT).

Untagged monoubiquitin was purified as described previously and polyubiquitin chains were synthesized and purified as described previously (Kristariyanto et al, 2015) .

Clarified lysate was incubated with GSH sepharose for 1hr. Resin was then washed with high salt buffer (500 mM NaCl, 50 mM Tris pH 7.5, 5 10 mM DTT) and then low salt buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1 mM DTT). Resin was incubated with low salt buffer supplemented with PreScission protease o/n at 4˚C to cleave the GST tag. Protein was eluted and concentrated (Amicon Centrifugal Filter Units, Merck) followed by size exclusion chromatography (Superdex 75 16/60, Cytiva) in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT.

Clarified lysate was incubated with His60 Ni Superflow Resin (TaKaRa). Resin was washed with a buffer (300 mM NaCl, 50 mM Tris pH 7.5) supplemented with increasing concentrations of imidazole. Protein was eluted with 300 mM Imidazole. Protein was eluted and concentrated (Amicon Centrifugal Filter Units, Merck) followed by size exclusion chromatography (Superdex 75 16/60, Cytiva) in a suitable buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT).

Clarified lysate was incubated with His60 Ni Superflow Resin (TaKaRa) for 1 hr at 4˚C.

Resin was washed with buffer (300 mM NaCl, 50 mM Tris pH 7.5) supplemented with increasing concentrations of imidazole. Protein was eluted with 300 mM Imidazole.

The eluent was then incubated with GSH Sepharose (BRAND) for 1 hour before being washed by high salt buffer (500 mM NaCl, 50 mM Tris pH 7.5, 5 10 mM DTT) and then low salt buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1 mM DTT). Resin was incubated with low salt buffer supplemented with PreScission protease o/n at 4˚C to cleave the GST tag. Protein was collected, loaded onto a 6 mL Resource Q column, and eluted in a gradient of buffer Q (50 mM Tris pH 8.5, 1000 mM NaCl). Peak fractions were concentrated (Amicon Centrifugal Filter Units, Merck) followed by size exclusion chromatography (Superdex 75 16/60, Cytiva) in a suitable buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT).

PLpro and Nsp3 were diluted in buffer A (50 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM DTT) to, and incubated at RT for 10 minutes to fully reduce the catalytic cysteine.

For most protease cleavage assays, 3 μM substrate was incubated with varying concentrations of PLpro and Nsp3. For assays comparing the relative activities of each proteaseagainst a panel of substrates and assessing the linkage specificity, 50 nM of Plpro/Nsp3 was used. For assays comparing the relative activities of PLpro and Nsp3 with Nsp1-2 FL, Ub3, proISG15 and Nsp1-2Δ the respective enzyme concentrations were 50 nM (Nsp1-2 FL, Ub3), 20 nM (proISG15) and 1 μΜ (Nsp1-2Δ). For the assay comparing the cleavage of Nsp1-2(Δ) G180A relative to WT by Nsp3 and the assay comparing cleavage of Nsp1-2Δ by all Nsp3 constructs, 5 μM protease was incubated with 10 μM substrate. For the assay in which increasing concentrations of PLpro were incubated with Nsp1-2Δ, 10 μM substrate was used. All assays were carried out at 30˚C and quenched at indicated time points by adding LDS loading dye. The samples were separated on 4-12% SDS-PAGE gel (Life Technology) and silver stained using Pierce Silver stain kit (Thermo Fisher).

HALO-Nsp1 thioester was generated following intein cleavage as described previously for ubiquitin (Borodovsky et al., 2002) . The HALO-Nsp1-thioester was buffer exchanged into HEPES buffer (pH 8.0) and reacted with 250 mM propargylamine (Sigma) for 3 hours at RT. The reactive probe was then separated from the excess propargylamine by size-exclusion chromatography (Superdex 200 16/60, Cytiva) in a suitable buffer (1x PBS). To test reactivity of the probe (S1B), 5 μM Nsp3/PLpro was incubated with 10 μM of HALO-Nsp1 prg at 30˚C for 1 hr. The reaction was quenched with 4x LDS dye, resolved on a 4-12% SDS-PAGE gel (Life Technology) and stained with InstantBlue (BRAND).

PLpro and Nsp3 were diluted in buffer I (50 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.01% (w/v) BSA). The DUB was pre-incubated with the indicated concentration of small molecule inhibitor/nanobody for 30 min at RT. A final concentration of 50 nM DUB was incubated with 3 μΜ substrate at 30˚C for 1 hour. The assay was quenched at indicated time points by adding LDS loading dye. The samples were separated on 4-12% SDS-PAGE gel (Life Technology) and silver stained using Pierce Silver stain kit (Thermo Fisher).

Clarified lysates containing 6His-GST-AVI-PLpro or 6His-GST-AVI-PLpro E912R E948R M953E Y1013K (S1* mutant) were incubated with His60 Ni Superflow Resin (TaKaRa) for 1 hr at 4˚C. Resin was washed with 300 mM NaCl, 50 mM Tris pH 7.5, 10 mM Imidazole, 2 mM BME and protein was eluted with added 300 mM Imidazole.

The eluted protein was concentrated to ~100 µM and biotinylated by incubation with 2 µM BirA, 5 mM MgCl2, 2 mM ATP and 250 µM Biotin for 1 h at 25 °C. Additional 250 µM Biotin were added and the reaction was incubated for 1 h at 25 °C. The reaction mix was then incubated with GSH Sepharose beads for 1 hour at 4 °C and the resin was washed with 50 mM Tris pH 7.5, 300 mM NaCl, 2 mM BME. The 6His-GST-tag was removed by incubation with PreScission protease overnight at 4 °C and the biotinylated protein was eluted from the resin, concentrated to ~1 mg/ml, flash-frozen in liquid nitrogen and stored at -80 °C. Successful biotinylation of the target protein was assessed through incubation with 5-fold excess streptavidin for 5 min at 20 °C, followed by SDS-PAGE analysis of the induced MW-shift of the streptavidin complex.

Site-specific nanobodies against PLpro were selected from the naïve yeast display nanobody library, which was developed and generously provided by the Kruse lab (McMahon et al 2018) . Yeast were grown in YGLC-glu medium (80 mM sodium citrate pH 4.5 (Sigma), 6.7 g/l yeast nitrogen base w/o amino acids (BD Biosciences), 2% glucose, 3.8 g/l Do mix-trp at 30 °C and 200 rpm shaking overnight and nanobody expression was induced by incubation in YGLC-gal medium (recipe as YGLC-glu but with galactose in place of glucose) at 20 °C and 200 rpm for 48-72 h. Nanobodyexpressing yeast were washed with and selected against in sterile-filtered, ice-cold PBM (1x PBS (Gibco) supplemented with 0.5% BSA (Sigma) and 5 mM Maltose (Sigma)). Nanobodies were selected in four rounds of magnetic cell sorting (MACS) on LD columns (Miltenyi) for negative selection against biotinylated PLpro S1* mutant and subsequent positive selection on LS columns (Miltenyi) against biotinylated PLpro. In the first MACS round, 5*10^9 yeast in 5 ml PBE were incubated with 400 nM biotinylated PLpro S1* mutant immobilized on Streptavidin microbeads (Miltenyi) for 40 min at 4°C. The mixture was applied to an equilibrated LD column on a magnetic rack, the flow-through was collected and the column was washed with 2 ml PBM to collect further unbound yeast. Unbound yeast was pelleted at 4°C and 2500 g for 3 min and resuspended in 5 ml PBM containing 400 nM biotinylated PLpro immobilised on streptavidin microbeads and rotated for 1 h at 4 °C. Yeast were pelleted as above, resuspended in 3 ml PBM and applied to an LS column on a magnetic rack. The column was washed three times with 3 ml PBM, removed from the magnetic rack and yeast were eluted with 5 ml PBM. Eluted yeast were pelleted, resuspended in 4 ml YGLC-glu and incubated at 30 °C and 200 rpm shaking overnight. The next day, yeast were used to inoculate 4 ml YGLC-gal at OD600=1 and incubated at 20 °C and 200 rpm for 48-72 h. For the second MACS selection rounds, 1*10^8 yeast were pelleted and resuspended in 500 µl PBM containing 100 nM Streptavidin-Alexa Fluor 647 conjugate (Thermo Fisher) and 400 nM PLpro S1*-mutant and incubated for 40 min at 4 °C. Yeast were washed with 1 ml PBM and resuspended in 950 µl PBM + 50 µl anti-Alexa647 microbeads (Miltenyi) and rotated for 20 min at 4 °C. Yeast were negatively selected on LD column as described above. Flow-through yeast were washed once with 1 ml PBM and resuspended 500 µl PBM containing 100 nM Streptavidin-Alexa647 and 400 nM biotinylated PLpro and incubated for 2 h at 4 °C. Yeast were washed with 1 ml PBM, resuspended in 950 µl PBM + 50 µl anti-Alexa647 microbeads and rotated for 20 min at 4 °C. Yeast were applied to and eluted from LS column for positive selection as described above. Yeast were recovered in YGLC-glu and incubated in YGLC-gal as above. The negative selection of the third and fourth MACS round were identical to the second round described above. For the positive selection of the third MACS round, the flow-through yeast was incubated with 2000 nM PLpro in 500 µl PBM for 1 h at 4 °C, washed twice with 1 ml PBM, resuspended in 50 nM Streptavidin-647 in 500 ml PBM and rotated for 15 min at 4 °C. Yeast was pelleted and resuspended in 5 ml PBM and positively selected on LS columns as described above.

The fourth MACS selection round was identical to the third round, but with reduced PLpro concentration (500 nM) for positive selection. The selection was monitored by flow cytometry on a cytoFLEX S (Beckman) by analysis of fluorescent signals of antigen-bound (Streptavidin-647) and total nanobodies (anti-HA-Alexa488, Cell

Signaling Technologies) displayed on the yeast surface.

Yeast obtained after four rounds of MACS selection was plated on YGLC-glu agar to obtain single colonies after 96 h at 30 °C. Single yeast colonies were picked and resuspended in 100 µl 200 mM lithium acetate and 1% SDS each. The cell suspension was incubated for 5 min at 70 °C and subsequently mixed with 300 µl ethanol and vortexed. The mixture was centrifuged at 15k g for 3 min, the pellet was washed with 70 % ethanol and resuspended in 100 µl H2O. Cell debris was removed by centrifugation at 15k g for 1 min and 1 µl of the supernatant was used as template DNA for 25 µl PCR reaction (KOD HotStart, Merck) with primers NbLib-fwd-i (CAGCTGCAGGAAAGCGGCGG) and NbLib-rev-i (GCTGCTCACGGTCACCTGG) to amplify the nanobody insert sequence. Nanobody PCR fragments were analyzed on 2% TAE-agarose gels and purified with the QIAquick gel extraction kit (Qiagen).

PCR fragments were sequenced and individual nanobodies were cloned using the In- 

The beads from HA-Nsp3, HA-PLpro and control immunoprecipitations were resuspended in 100 µl of 100mM Tris-Cl (pH 8.0 Precursor ions were isolated using quadrupole mass filter with 0.7 Da mass window and MS2 spectra was fragmented using collisional induced dissociation and recorded using Iontrap mass analyzer in a rapid mode. Top 10 fragment ions with a 1.2 Da isolation window was isolated and fragmented using beam-type collisional induced dissociation (HCD) at 65% normalized collision energy and analyzed using Ultra-high filed Orbitrap mass analyzer using 50,000 resolution at m/z 200. The AGC targets were set as 2E5 for MS1, 2E4 for MS2 and 5E4 for MS3 with 100 ms, 54 ms and 120 ms ion injections respectively.

The MaxQuant software suite (Tyanova et al, 2016) kDa) signals. 4000 laser shots per sample spot were accumulated in positive ionization mode using a 500 ns pulsed ion extraction with a 10 kHz laser frequency, a digitizer setting of 5.00 GS/s, and a single Smartbeam parameter at a 800 µm scan range. The acquired spectra were processed with a centroid peak detection set to a signal-tonoise ratio (S/N) of 5 and Gaussian smoothing (0.5 m/z; 10 cycle). The signal of 15 N ubiquitin was added to the mass control list and used as internal calibrant. MALDI-TOF data, processed with flexAnalysis were exported as a comma delimited (.csv) file.

Data sets were further processed using Excel or GraphPad Prism (v7.03; GraphPad Software, La Jolla, CA). PLpro activity was tracked using the measured area (signal) of the enzymatic product (ubiquitin) and the corresponding labelled internal standard ( 15 N ubiquitin). All data points were reported as ratio of ubiquitin signal over the internal standard signal. Generated sample data were expressed as percentage of control (PoC) according to the following equation:

Were b being the average of the negative controls and c the average of the positive controls.

To assess the robustness and quality of the hit discovery campaign a key metric, the Z' parameter (Zhang et al, 1999) was employed as for following equation:

Were σp, σn being positive and negative control standard deviations and μp, μn the difference of the averages of positive and negative controls. GraphPad Prism was utilized for graphical representation of the data. 

New World and Old World Alphaviruses Have Evolved to Exploit Different Components of Stress Granules, FXR and G3BP Proteins, for Assembly of Viral Replication Complexes

Global BioIDbased SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms

Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein

FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication

Yeast surface display platform for rapid discovery of conformationally selective nanobodies

Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV replication

Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like Protease

Screening of DUB activity and specificity by MALDI-TOF mass spectrometry

Auranofin: Repurposing an Old Drug for a Golden New Age

The FDAapproved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response

Lenschow DJ & Huibregtse JM (2020) 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities

The SARS-Unique Domain (SUD) of SARS coronavirus contains two macrodomains that bind G-quadruplexes

The MaxQuant computational platform for mass spectrometry-based shotgun proteomics

Double-Membrane Vesicles as Platforms for Viral Replication

A simple statistical parameter for use in evaluation and validation of high throughput screening assays

We thank members of the Kulathu lab for discussions and help, 

His6-GST-Nsp3 ( (2007) 

A) Schematic workflow of yeast-surface display selection to identify site-specific nanobodies as competitive Nsp3 inhibitors.

Flow cytometry analysis of yeast displaying anti-Nsp3 nanobodies NbSL17, NbSL18 or NbSL19, respectively. Yeast were stained with anti-HA-Alexa488 against HA-tagged Nb and Streptavidin-Alexa647 against biotinylated antigens. Top: Yeast incubated with PLpro wild-type, Bottom: Yeast incubated with PLpro S1*-mutant. Percentages indicate fraction of yeast positive for both fluorescent labels. C) UV-traces and coomassie-stained SDS-PAGE of analytical gel filtration analyses of PLpro-Nb complexes. PLpro alone (black), PLpro+NbSL17 (orange) and PLpro+NbSL18 (blue).

Isothermal calorimetry titration measuring binding of PLpro to NbSL18 (D), ISG15 (E) or K48-Ub2 (F). G) Silver stained gels of DUB assays of PLpro (left) and Nsp3 (right) with K48-Ub3 (top) and proISG15 (middle) and Nsp1-2 FL (bottom) as substrates in the presence of increasing concentrations of NbSL18. Silver-stained SDS-PAGE gels. Also see Figure S4 . Figure S4 : Design of PLpro S1*-mutant and identified inhibitory nanobody sequences A) Structure of SARS-CoV PLpro (blue) bound to Ubiquitin (green) (PDB 4MM3). Stick models show mutated S1-binding site residues (gold) and catalytic cysteine C856. Labels indicate right-hand architecture of PLpro with Fingers, Palm and Thumb subdomains.

Coomassie stained gel comparing reactivity of PLpro WT and the S1* mutant with Ub-prg C) DUB assay of PLpro WT and the S1* mutant with K48-Ub3 as substrate visualized by silver staining D-E) DUB assays of PLpro (D) and Nsp3 (E) with K48-Ub3 (top) and proISG15 (bottom) in the presence of increasing concentrations of NbSL17. F) Sequence alignment of identified inhibitory nanobodies NbSL17, NbSL18 and NbSL19 with synthetic nanobody Nb.201 (PDB 5VNV). Secondary structure elements and location of complementarity determining regions (CDRs) are indicated above the sequence.